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Background: Excessive levels of methylglyoxal (MG) encountered in diabetes foster enhanced leukocyte-endothelial cell
interactions, mechanisms of which are incompletely understood. MG genomically upregulates endothelial serum- and
glucocorticoid-inducible kinase 1 (SGK1) which orchestrates leukocyte recruitment by regulating the activation and
expression of transcription factors and adhesion molecules. SGK1 regulates a myriad of ion channels and carriers including
the Na+/H+ exchanger NHE1. Here, we explored the effect of MG on SGK1-dependent NHE1 activation and the putative
role of NHE1 activation in MG-induced leukocyte recruitment and microvascular hyperpermeability.
Methods: Using RT-PCR and immunoblotting, we analyzed NHE1 mRNA and protein levels in murine microvascular
SVEC4-10EE2 endothelial cells (EE2 ECs). NHE1 phosphorylation was detected using a specific antibody against the
14-3-3 binding motif at phospho-Ser703. SGK in EE2 ECs was silenced using targeted siRNA. ROS production was
determined using DCF-dependent fluorescence. Leukocyte recruitment and microvascular permeability in murine
cremasteric microvasculature were measured using intravital microscopy. The expression of endothelial adhesion
molecules was determined by immunoblotting and confocal imaging analysis.
Results: MG treatment significantly upregulated NHE1 mRNA and dose-dependently increased total- and phospho-NHE1.
Treatment with SGK1 inhibitor GSK650394, antioxidant Tempol and silencing SGK all blunted MG-triggered
phospho-NHE1 upregulation in EE2 ECs. NHE1 inhibitor cariporide attenuated MG-triggered ROS production, leukocyte
adhesion and emigration and microvascular hyperpermeability, without affecting leukocyte rolling. Cariporide treatment
did not alter MG-triggered upregulation of P- and E-selectins, but reduced endothelial ICAM-1 expression.
Conclusion: MG elicits SGK1-dependent activation of endothelial Na+/H+ exchanger NHE1 which participates in
MG-induced ROS production, upregulation of endothelial ICAM-1, leukocyte recruitment and microvascular
hyperpermeability. Pharmacological inhibition of NHE1 attenuates the proinflammatory effects of excessive MG
and may, thus, be beneficial in diabetes-associated inflammation.
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Increased interaction of leukocytes with activated vascu-
lar endothelium participates in the inflammatory seque-
lae of diabetes [1-3]. Excessive levels of the glycolysis
metabolite methylglyoxal (MG) in vivo, that contribute
to increased carbonyl stress, are associated with conditions* Correspondence: lixin.liu@usask.ca
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unless otherwise stated.such as diabetes, renal failure, obesity and metabolic syn-
drome [4-9]. In diabetes, increased levels of MG are impli-
cated in the pathogenesis of vascular complications such
as hypertension [10], impaired microcirculation [11], and
thrombosis [12]. Ramifications of pathological MG con-
centrations include modulation of immune cell functions
by stimulation of cytokine induction [13], activation of
macrophages [14], and suppression of T-cell functions
[15]. MG alters cellular functions by influencing energy
and redox balance [16], modulating cytosolic Ca2+ [17]
and by triggering apoptotic or necrotic cell death [11,18].td. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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betes by enhancing neutrophil apoptosis and by eliciting
the expression of integrins on neutrophils [12]. Recently,
MG was shown to stimulate leukocyte-endothelial cell
interactions by reducing intravascular rolling velocity
and by potentiating adhesion and transendothelial mi-
gration of leukocytes through the upregulated endothe-
lial adhesion molecules [19]. MG was shown to induce
eNOS uncoupling [20] which supports redox-sensitive
leukocyte recruitment and enhanced microvascular per-
meability during inflammation [21]. However, putative
mechanisms of MG-induced leukocyte recruitment are
largely unknown.
MG-induced leukocyte recruitment was recently re-
ported to be mediated by signal transduction down-
stream of endothelial phosphoinositide 3-kinases (PI3K)
[22]. MG was shown to temporally activate glycogen
synthase kinase 3 (GSK3) and serum- and glucocorticoid-
inducible kinase 1 (SGK1) which, in turn, stimulate endo-
thelial nuclear factor-κB (NF-κB) and cyclic AMP response
element-binding protein (CREB), two transcription factors
that are important in mediating inflammatory responses
[22]. The kinase SGK1, ubiquitously expressed and regu-
lated by a myriad of cell stressors [23], is genomically up-
regulated in endothelial cells in response to MG treatment
[22]. SGK1 regulates a wide array of ion channels and car-
riers including the Na+/H+ exchangers NHE1 and NHE3
[24-29]. Phosphorylation of NHE1 Ser703 by SGK1 is es-
sential for the binding of 14-3-3 protein to NHE1 [25,30]
which, in turn, is critical in the activation of this Na+/H+
exchanger [25,31].
The plasma membrane transport protein NHE1 regu-
lates cellular pH and volume and, thus, participates in a
multitude of physiological functions such as prolifera-
tion, migration and apoptosis [32]. Endothelial cells
express the Na+/H+ exchanger isoforms NHE1 and
NHE2 that regulate functions such as endocytosis [33],
apoptosis [34] and blood brain barrier [35-38]. NHE1
is constitutively phosphorylated and additional phos-
phorylation enhances its activity [39]. Several studies
have documented that reactive oxygen species (ROS)-
mediated signaling activates NHE1 [24,40]. Na+/H+ ex-
change is pharmacologically inhibitable by NHE1-selective
acylguanidine-derived compounds such as cariporide
(HOE-642) [39,41,42]. Cariporide blunts the phosphoryl-
ation of NHE1 [31] and has been widely used to study pu-
tative functions of NHE1 in vitro and in vivo [24,41,43,44].
The influence of MG on NHE1 expression and functions
remains elusive.
The present study explores the mechanisms in-
volved in the activation of endothelial NHE1 by MG.
Using intravital microscopy, which enables us to dir-
ectly visualize and determine leukocyte-endothelial inter-
actions with high imaging quality in the microvasculatureof anaesthetised mice, we elucidate the effects of pharma-
cological suppression of NHE1 on leukocyte recruit-
ment and microvascular hyperpermeability elicited by
MG.
Materials and methods
Mice and intravital microscopy
Male C57BL/6 mice (Charles River, Saint-Constant, QC,
Canada) aged 8–12 wk-old were used in this study
with the approval of animal protocols from University
Committee on Animal Care and Supply (#20070028)
at the University of Saskatchewan. Mice were anaes-
thetised using an i.p. injection of 10 mg/kg xylazine
(Bayer, Toronto, ON, Canada) and 200 mg/kg ketamine
hydrochloride (Rogar, Montreal, QC, Canada). The mouse
cremaster muscle preparation was used to study dy-
namic leukocyte-endothelial interactions in micro-
vasculature as described [21,22,45,46]. The cremaster
muscle microvasculature is considered to be the gold-
standard in vivo model for intravital microscopy where
leukocyte-endothelial cell interactions in the postcapil-
lary venules are readily visualized [47]. Leukocyte roll-
ing flux (cells/min), velocity of rolling leukocytes (μm/sec),
and the number of adherent (cells/100-μm venule)
and emigrated leukocytes (cells/443 × 286 μm2 field)
were determined in the cremasteric postcapillary ven-
ule (25–40 μm diameter) using video playback analysis
[21,22,45,46]. MG-triggered microvascular leakage was
determined in postcapillary venules of the cremaster
muscle by intravital microscopy measuring fluores-
cence intensity of FITC-labelled BSA (25 mg/kg i.v.;
Sigma) inside and outside the vessel for calculating per-
meability index as described [21,45]. Where indicated,
MG (50 mg/kg; Sigma, Oakville, ON, Canada) and car-
iporide (20 mg/kg, Sigma) were administered by separ-
ate intrascrotal injections or superfusion of exposed
cremaster muscle with MG and cariporide at 100 μM
and 50 μM, respectively.
Cell culture and gene silencing
Murine microvascular SVEC4-10EE2 endothelial cell
line cells (EE2 ECs; ATCC, Manassas, VA) were cul-
tured as described earlier [22]. Previously, MG-sensitive
SGK1 signaling was studied in EE2 ECs [22] and in the
present study we elucidate the role of NHE1 in MG-
induced leukocyte recruitment in the context of SGK1-
dependent activation of NHE1. We, therefore, used EE2
ECs to corroborate our in vivo findings. Where indi-
cated, Tempol (300 μM; Sigma), cariporide (50 μM) or
GSK650394 (20 μM; Sigma) was added at the specified
concentrations. Targeted gene silencing was accom-
plished by a 48-h transfection of EE2 ECs with siRNA
specifically targeting SGK (Santa Cruz) and with siRNA
transfection medium and reagent (Santa Cruz) as described
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negative control scrambled siRNA (Santa Cruz) having no
homology to any known RNA sequence.
RT-PCR
RT-PCR was performed to determine NHE1 and β-actin
mRNA expression as described previously [22]. Briefly,
RNA was isolated from the cells using RNA isolation kit
(Qiagen) and reverse-transcribed using reverse transcrip-
tion kit (Qiagen). RT-PCR was carried out by SYBR
green PCR kit (Qiagen) in an iCycler iQ apparatus
(Bio-Rad, Hercules, CA) with primers targeting NHE1
(QT00105413; Qiagen) and β-actin (QT00095242; Qiagen).
All PCRs were performed in triplicate and ran for
30 cycles at 95°C for 30 sec, 55°C for 30 sec, and 72°C for
40 sec.
Immunoprecipitation and immunoblotting
Phosphorylation of NHE1 was determined in NHE1-
immunoprecipitated samples using an anti-phospho-
(Ser) 14-3-3 protein binding motif antibody [25]. Briefly,
EE2 ECs or excised cremaster muscles were harvested
using ice-cold IP lysis buffer containing complete prote-
ase and phosphatase inhibitor cocktail (Cell Signaling)
and the samples were sonicated on ice three times for
5 seconds each. The protein concentration was determinedFigure 1 Methylglyoxal-induced upregulation of NHE1 expression. (A) R
total NHE1 and phospho-NHE1 (14-3-3 binding motif at p-Ser703) determined
significant difference (p < 0.05) from 0 μM MG. (B) Mean ± SEM of NHE1 mRN
(relative to β-actin). * indicates significant difference (p < 0.05) from 0 h. (C) Re
NHE1 and phospho-NHE1 (14-3-3 binding motif at p-Ser703; relative to β-actin)
with saline (Control) or MG (50 mg/kg). * indicates significant difference (p < 0.by BCA assay (Sigma). The samples were then aliquoted
into two equal portions of 500 μg proteins each. In the
first portion, β-actin (Santa Cruz) was detected as de-
scribed previously [22]. In the second portion, lysates
containing 500 μg proteins were incubated overnight
at 4°C with 5 μl mouse monoclonal NHE1 antibody
(Abcam). Then, immune complexes were mixed with
protein G agarose (20 μl of 50% bead slurry, Thermo
Fisher Scientific) for 3 h at 4°C and then washed five
times with ice-cold IP lysis buffer. The immune com-
plexes were dissociated by adding 20 μl 3× SDS sample
buffer and heating for 5 min at 95°C, and then centri-
fuged for 1 min at 14,000× g for removing the agarose
beads. The resulting supernatant was separated into
two equal portions. One portion of the protein lysate
was separated on 10% SDS-PAGE gels and electrotrans-
ferred to a nitrocellulose membrane. The membrane
was incubated overnight at 4°C with rabbit polyclonal
phospho-(Ser) 14-3-3 binding-motif protein antibody
(1:1000, Cell Signaling), followed by 2-h incubation
with HRP-conjugated goat anti-rabbit secondary anti-
body (1:1000, Santa Cruz) at room temperature. In the
other portion, total NHE1 (1:1000, Abcam) was deter-
mined respectively using routine immunoblotting [45].
Where indicated, expression of adhesion molecules was
detected in cremaster muscle homogenates as describedepresentative original Western blot and means ± SEM (n = 4) showing
in MG-treated (0–200 μM for 4 h) EE2 ECs (relative to β-actin). * indicates
A levels (n = 4) determined in MG-treated (100 μM for 0–8 h) EE2 ECs
presentative original Western blot and means ± SEM (n = 4) showing total
determined in excised cremaster muscle 4 h after an intrascrotal injection
05) from the absence of MG (Control).
Qadri et al. Cardiovascular Diabetology 2014, 13:134 Page 4 of 12
http://www.cardiab.com/content/13/1/134previously [19,22] using primary antibodies against
ICAM-1 (Abcam), P-selectin (LifeSpan Biosciences)
and E-selectin (Abcam). Intensity values for the proteins
were normalized to β-actin and densitometric quantifica-
tion of the detected bands was performed using Quantity
One® Software (Bio-Rad).
Determination of ROS production
The levels of ROS production in EE2 ECs were mea-
sured as previously described [21]. Following the in-
dicated treatments, EE2 ECs were loaded (30 min,
37°C in the dark) with a membrane-permeable and
non-fluorescent 2’,7’-dichlorodihydrofluorescein diace-
tate (H2DCFDA; 30 μM, Invitrogen) which was oxi-
dized to fluorescent 2’,7’-dichlorofluorescein (DCF) inFigure 2 Methylglyoxal-triggered endothelial SGK-dependent NHE1 acti
(B; n = 4) showing total NHE1 (white bars) and phospho-NHE1 (14-3-3 bin
the absence (Control) or in the presence of MG-treatment (100 μM for 4
(20 μM, 1 h prior to MG). * indicates significant difference (p < 0.05) from
from MG alone. C − E. Representative original Western blot (C) and mean
binding motif at p-Ser703; relative to β-actin; E) determined in MG-treated
black bars) or with SGK-targeted siRNA silencing (white bars). * indicates sign
(p < 0.05) from scrambled control siRNA.the presence of ROS. To remove excess probe, the cells
were washed with PBS and fluorescence intensity in
EE2 ECs was excited at 495 nm and measured at
527 nm emission wavelengths. Data are normalized to
the control.
Confocal imaging
EE2 ECs treated under different conditions were fixed
using 4% paraformaldehyde for 30 min, washed twice
with PBS, blocked for 1 h with 5% goat serum (Abcam)
and then incubated overnight at 4°C with antibodies
against ICAM-1 (1:500; eBioscience). After washing, the
slides were incubated for 1 h with fluorescence goat
anti-rat antibody (Alexa Fluor 488; Invitrogen) and the
cells were then washed, permeabilized with 0.1% Tritonvation. A− B. Representative original Western blot (A) and means ± SEM
ding motif at p-Ser703; black bars; relative to β-actin) determined in
h) in EE2 ECs without (MG) or with the SGK1 inhibitor GSK650394
the Control (0 μM MG). # indicates significant difference (p < 0.05)
s ± SEM (n = 4) showing total NHE1 (D) and phospho-NHE1 (14-3-3
(100 μM for 0–8 h) EE2 ECs with scrambled siRNA (Control siRNA;
ificant difference (p < 0.05) from 0 h. # indicates significant difference
Figure 3 Contribution of oxidative stress in methylglyoxal-
triggered endothelial NHE1 activation. (A) Means ± SEM (n = 6) of
DCF-dependent fluorescence in EE2 ECs treated with MG (100 μM
for 0–8 h) alone (MG) or co-treated with MG and cariporide (50 μM;
1 h prior to MG) or Tempol (300 μM; 1 h prior to MG). * indicates
significant difference (p < 0.05) from MG alone. (B) Representative
original Western blot and means ± SEM (n = 4) showing total NHE1
and phospho-NHE1 (14-3-3 binding motif at p-Ser703; relative to
β-actin) determined in EE2 ECs treated with MG (100 μM for 1 h)
alone or co-treated with MG and cariporide (50 μM; 1 h prior to MG)
or Tempol (300 μM; 1 h prior to MG). * indicates significant difference
(p < 0.05) from the absence of MG (Control). # indicates significant
difference (p < 0.05) from MG alone.
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slides were mounted in ProLong® Gold Antifade Reagent
(Invitrogen) and observed under a laser scanning confocal
microscope (Zeiss, LSM 700). As the antibodies recognize
extracellular epitopes of target proteins, the labelled pro-
teins are considered to have surface localization.
Statistical analysis
Data are shown as arithmetic mean ± SEM. Statistical
analysis was made using ANOVA with Tukey’s post-hoc
comparison test. n denotes the number of different mice,
different batches of cremaster muscle or endothelial cells
studied in each group. Values of p < 0.05 were consid-
ered statistically significant.
Results
Firstly, we tested whether MG treatment influences
endothelial NHE1 protein levels. We found that treat-
ment of EE2 ECs with MG significantly enhanced NHE1
and phospho-NHE1 in a dose-dependent manner, an effect
reaching statistical significance at 100 μM MG (NHE1)
and 50 μM (phospho-NHE1) respectively (Figure 1A).
Next, we determined whether MG influences NHE1
transcription in EE2 ECs. As shown in Figure 1B,
treatment of EE2 ECs with MG for 0–8 h significantly
enhanced NHE1 mRNA levels, an effect reaching stat-
istical significance 2 h after MG treatment. To corrob-
orate our in vitro observations, we demonstrate that
an intrascrotal injection of MG for 4 h significantly
upregulated total- and phospho-NHE1 levels in cre-
master muscle (Figure 1C).
We then sought to elucidate the participation of SGK1
in the activation of endothelial NHE1 elicited by MG
treatment. As shown in Figure 2A and B, MG treat-
ment (100 μM) of EE2 ECs significantly upregulated
total NHE1 and phospho-NHE1 as compared to the
control. Treatment with the SGK1 inhibitor GSK650394
significantly attenuated MG-induced upregulation of
phospho-NHE, but not total NHE1 (Figure 2A and B).
To confirm the role of SGK1 in NHE1 activation, an
additional series of experiments were performed using
SGK-targeted siRNA silencing. As illustrated in Figure 2C
and D, MG treatment significantly enhanced NHE1 pro-
tein expression in EE2 ECs at 4–8 h after MG treatment,
an effect that was not significantly altered by SGK silen-
cing. Furthermore, phospho-NHE1 levels in EE2 ECs were
significantly enhanced at 1–8 h after MG treatment, an ef-
fect that was abolished by SGK silencing (Figure 2C and
E). These data suggest that endothelial SGK1 activates
NHE1 in response to MG treatment.
To address the role of oxidative stress in MG-induced
NHE1 activation, we analyzed ROS generation. Figure 3A
shows that MG treatment significantly enhanced DCF-
dependent fluorescence in a time-dependent manner,an effect that was significantly curtailed by treatment
with cariporide or the antioxidant Tempol. These data
indicate that NHE1 activation is required for MG-
triggered ROS production. An additional series of
experiments explored whether MG-induced ROS pro-
duction [20] is essential as an upstream activator of
endothelial NHE1. As shown in Figure 3B, total NHE1
expression in EE2 ECs was significantly upregulated
after treatment with MG, an effect that was signifi-
cantly blunted by the antioxidant Tempol but not by
cariporide. In contrast, MG-triggered enhanced phospho-
NHE1 expression was significantly reduced by both
Tempol and cariporide treatment suggesting that MG-
induced ROS production is crucial for NHE1 activa-
tion and both oxidative burst and NHE1 activation
depend on each other in response to MG treatment
(Figure 3B).
Next, we explored whether SGK1-dependent NHE1 acti-
vation participates in MG-induced leukocyte recruitment.
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culature revealed increased adhesion to endothelium
and emigration of leukocytes following MG treatment,
an effect that was thwarted by cariporide treatment
(Figure 4). Analysis of leukocyte recruitment 4.0 − 5.5 h
after an intrascrotal injection of MG showed decreased
leukocyte rolling velocity and increased leukocyte rolling
flux, adhesion and emigration as compared to saline con-
trol (Figure 4B-E). Pretreatment with cariporide, however,
significantly blunted MG-induced increased leukocyteFigure 4 Effect of cariporide on methylglyoxal-induced leukocyte rec
adherent (white arrowheads) and emigrated (black arrowheads) leukocytes. B −
velocity (μm/sec; C), adhesion (cells/100-μm venule; D) and emigration (cells/4
of saline (Control) or MG (50 mg/kg) alone or co-treated with MG and cariporid
from MG alone.adhesion and emigration but did not modify leukocyte
rolling flux and velocity (Figure 4B-E) indicating that
NHE1 activation participates in leukocyte recruitment in
response to excessive MG. Cariporide treatment reduced
leukocyte adhesion by ~25% and emigration by ~34% at
5.5 h after MG treatment.
Impaired microvascular barrier function during leukocyte
transendothelial migration fosters increased micro-
vascular permeability. We, therefore, measured fluores-
cence changes of FITC-conjugated albumin inside andruitment. (A) Representative intravital microscopy images showing
E. Means ± SEM (n = 6) of leukocyte rolling flux (cells/min; B), rolling
43 × 286 μm2 field; E) determined 4.0 − 5.5 h after an intrascrotal injection
e (20 mg/kg, 1 h prior to MG). * indicates significant difference (p < 0.05)
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effect of cariporide treatment on MG-elicited micro-
vascular leakage. As depicted in Figure 5, permeability
index analysis revealed that an intrascrotal injection of
MG increased microvascular permeability, an effect that
was significantly inhibited by treatment with cariporide.
These data indicate that NHE1 activation participates in
MG-triggered increases in microvascular permeability.
To identify the mechanisms that regulate sensitivity of
MG-induced leukocyte recruitment to cariporide, we an-
alyzed the expression of endothelial adhesion molecules.
Murine cremaster muscles treated with MG had en-
hanced expression of P- and E-selectins and ICAM-1.
Cariporide treatment attenuated MG-induced ICAM-1
expression, but not P- and E-selectin expression in vivo
(Figure 6A). To confirm these observations, we used
confocal microscopy to visualize the surface expression
of ICAM-1 on murine EE2 ECs. As shown in Figure 6B,
MG treatment enhanced the expression of ICAM-1 on
EE2 ECs, an effect that was blunted by cariporide treat-
ment. These results confirm that inhibition of NHE1 in
endothelial cells blunted MG-induced leukocyte adhe-
sion and transmigration through the suppression of
ICAM-1 upregulation indicating that MG-triggered acti-
vation of NHE1 regulates ICAM-1 upregulation and
ICAM-1-mediated endothelial functions.
Discussion
The present study reveals the role of SGK1-dependent
activation of endothelial NHE1 in regulating leukocyte
recruitment through the upregulation of ICAM-1 in
response to MG. We observed that MG treatment
potentiated dose- and time-dependent endothelial NHE1
mRNA and protein levels and triggered SGK1- and ROS-Figure 5 Effect of cariporide on methylglyoxal-induced microvascu
images (arrows point to the segment of postcapillary venule where per
permeability index analysis of mouse cremasteric postcapillary venules s
and after an intrascrotal injection for 4 h with saline (Control), MG (50 m
1 h prior to MG). * indicates significant difference (p < 0.05) from the ab
from MG alone.dependent NHE1 phosphorylation. By using intravital mi-
croscopy of cremasteric microvasculature in a previously
described murine model of MG-triggered acute inflamma-
tion [19,21,22], we demonstrate that pharmacological in-
hibition of NHE1 using cariporide ameliorated leukocyte
adhesion, transendothelial migration and microvascular
leakage elicited by MG. Although, the decrease may not
appear dramatic in terms of absolute recruited cell num-
bers presented in the data, it turns out to be a significant
and stable difference in terms of inhibition of leukocyte
recruitment in vivo which was determined in a small
segment of the postcapillary venule. The physiological
relevance of MG concentrations used in this study is
corroborated by previous reports [49,50]. Intrascrotal in-
jection of MG (50 mg/kg) was shown to yield MG concen-
trations of 1.7 μM and 3.9 nmol/mg protein in plasma and
tissue respectively [19]. MG concentrations detected in
cremaster muscle are similar to those detected in other
organs [51,52]. Moreover, the concentration of MG
(100 μM) used in vitro in the present study is based on
previous reports [53-55].
Here, we show that MG treatment increased the levels
of both total and phosphorylated endothelial NHE1.
Mounting evidence suggests that NHE1 participates in
the pathogenesis of various complications of diabetes.
Recently, high glucose concentrations were demon-
strated to stimulate p38 MAPK- and ERK1/2-dependent
NHE1 activation in distal nephron cells [56]. Strikingly,
hyperglycemia was shown to induce endothelial dysfunc-
tion via Ca2+-dependent calpain signaling mediated by
the Na+/H+ exchanger [57]. In diabetic rats, vascular
hypertrophy was accompanied by elevated NHE1 activity,
an effect thwarted by cariporide administration [58]. Car-
iporide treatment was also found to ameliorate retinallar leakage. (A) Representative fluorescence intravital microscopy
meability index was determined) and (B) means ± SEM (n = 4) of
howing the leakage of FITC-conjugated BSA post 1-h i.v. injection
g/kg) alone or co-treatment with MG and cariporide (20 mg/kg,
sence of MG (Control). # indicates significant difference (p < 0.05)
Figure 6 Effect of cariporide on methylglyoxal-induced upregulation of endothelial adhesion molecule expression. (A) Representative
original Western blot and means ± SEM (n = 4) showing the expression of P-selectin, E-selectin and ICAM-1 (relative to β-actin) determined in
whole cremaster muscle 4 h after an intrascrotal injection of saline (Control), MG (50 mg/kg) alone or co-treated with MG and cariporide
(20 mg/kg, 1 h prior to MG). * indicates significant difference (p < 0.05) from absence of MG (Control). # indicates significant difference (p < 0.05)
from MG alone. (B) Representative confocal micrographs of cell surface ICAM-1 immunostaining (Red) in EE2 ECs in the absence (Control)
or in the presence of MG (100 μM, 4 h) alone or co-treatment with MG and cariporide (50 μM, 1 h prior to MG). Nuclear staining is shown
in blue (Hoechst 33342).
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hyperglycemia-induced hypertrophy of rat cardiomyo-
cytes [60]. Chronic cariporide administration was further
shown to attenuate left ventricular hypertrophy in dia-
betic rats [61]. Intriguingly, cariporide treatment was
shown to counteract the formation of methylglyoxal-
derived advanced glycation end products (AGEs) in type
1 diabetic rats [62]. AGEs, in turn, are known to amplify
inflammatory responses [63]. It is, therefore, tempting to
speculate that enhanced MG levels may contribute to or
even account for NHE1-mediated cardiovascular dysfunc-
tions encountered in diabetic complications.
Mechanistically, PI3K signaling is decisive in NHE1-
mediated cellular functions [64,65]. SGK1 is activated
through PI3K and phosphoinositide-dependent kinase
PDK1 [23,66]. The PI3K downstream kinase AKT waspreviously shown to phosphorylate and inhibit NHE1
[67]. Along these lines, SGK1 may play a decisive role in
PI3K-dependent NHE1 regulation. It was reported that
MG treatment did not alter SGK1 expression in neutro-
phils [22]. Accordingly, it is unlikely that cariporide
treatment inhibits MG-induced leukocyte recruitment
in vivo by mitigating neutrophil NHE1 activity. MG-
induced leukocyte recruitment may, therefore, be effect-
ively accomplished by activation of SGK1-dependent
NHE1 activation in endothelial cells.
Redox imbalance is an essential pathological element
of the diabetic milieu [68]. MG is known to stimulate
ROS and superoxide production [16,20-22]. Further-
more, MG modulates the expression and functions of
antioxidant cytoprotective molecules such as superoxide
dismutase and H2S [69,70]. Compelling evidence links
Figure 7 Scheme of the role of Na+/H+ exchanger NHE1 in
methylglyoxal-induced leukocyte recruitment.
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of NHE1 by cariporide was shown to blunt ROS formation
in dendritic cells [40]. Conversely, antioxidant treatment is
known to attenuate NHE activity [71]. Interestingly, ROS
was previously shown to enhance NHE1 gene expression
[72]. Thus, it is apparent from our data that ROS produc-
tion and NHE1 activation upon stimulation with MG are
dependent on each other.
Previous studies have shown a crucial role of NHE-
dependent functions in the brain microvascular endothe-
lium [36-38]. These studies, however, preclude us to
draw mechanistic parallels of NHE-dependent functions
in brain microvascular endothelial cells to peripheral
endothelial cells due to their distinct features. Upregula-
tion of adhesion molecules in diabetes is fostered by
hyperglycemia [73-75] and increased levels of MG [19].
We observed that cariporide treatment did not alter
selectin-dependent leukocyte rolling during MG-induced
leukocyte recruitment in vivo but mitigated endothelial
ICAM-1-dependent leukocyte adhesion. Surprisingly,
thrombin-induced P-selectin upregulation and leukocyte
rolling were reported to be inhibited by cariporide [76].
Cariporide treatment was shown to mitigate increased
ICAM-1 mRNA levels in microvascular endothelial cells
following ischemia-reperfusion [77] and to foster in-
creased shedding of L-selectin on leukocytes [78]. Re-
markably, cariporide treatment was found to decrease
monocyte adhesion to endothelial cell, an effect that
was attributed to decreased ICAM-1 expression [79].
Pharmacological blockade of NHE was previously re-
ported to suppress NF-κB activation [80], an effect
that contributes to reduced ICAM-1 expression [81].
Cariporide may, in addition, counteract inflammation
by abating cytokine production [82].
MG was previously shown to trigger increased micro-
vascular permeability [21], an effect mediated by oxida-
tive stress [21,83]. Our data reveal that NHE1 inhibition
attenuated MG-triggered microvascular hyperpermeabil-
ity. However, whether NHE1 activation directly regulates
microvascular barrier function is not known. It is possible
that reduction in MG-triggered microvascular hyperper-
meability after cariporide treatment results from the
suppression of NHE1 activation which regulates both
oxidative stress and transendothelial migration of leu-
kocytes, key elements that are vital to the microvascu-
lar permeability regulation [83,84]. By the same token,
leukocyte recruitment is also triggered by oxidative
stress [21,85] and our data suggests that inhibition of
MG-induced leukocyte recruitment by cariporide in-
volves a redox-sensitive mechanism.
Conclusions
In conclusion, MG elicits SGK1-dependent activation of
endothelial Na+/H+ exchanger NHE1 which participatesin MG-induced ROS production, upregulation of endo-
thelial ICAM-1, leukocyte recruitment and microvascular
hyperpermeability (Figure 7). Pharmacological inhibition of
NHE1 attenuates the proinflammatory effects of excessive
MG and may, thus, be beneficial in diabetes-associated
inflammation.
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